Green Sandy M, Green Jamie A, Januzzi James L
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Am J Ther. 2009 Mar-Apr;16(2):171-7. doi: 10.1097/MJT.0b013e318172797f.
Acutely destabilized heart failure is one of the most common diagnoses in the modern health care system. It has high hospital readmission rates and significant short-, medium-, and long-term mortality, likely due to misdiagnosis or failure to assess adequate treatment before discharge. Cardiac biomarkers such as B-type natriuretic peptide and its amino terminal cleavage equivalent N-terminal fragment have rapidly become one of the key tools in the diagnosis and guidance of heart failure therapy. In this article, we shall review the data on the current use of the natriuretic peptides for the diagnosis, prognosis, and management of heart failure in both the outpatient and inpatient settings.
急性失代偿性心力衰竭是现代医疗体系中最常见的诊断之一。其住院再入院率高，且有显著的短期、中期和长期死亡率，这可能是由于误诊或出院前未评估充分治疗所致。心脏生物标志物如B型利钠肽及其氨基末端裂解等效物N末端片段已迅速成为心力衰竭诊断和治疗指导的关键工具之一。在本文中，我们将回顾利钠肽在门诊和住院环境中用于心力衰竭诊断、预后和管理的当前数据。
